Do You Have to Increase Wegovy Dose Every Month, or Can You Stay at a Lower Dose?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved Wegovy protocol requires monthly dose increases from 0.25 mg to 2.4 mg over 16 to 20 weeks, but clinical practice allows pausing or stopping escalation if you reach your weight goal or experience intolerable side effects.
• Staying at a lower maintenance dose (commonly 1.7 mg or 1 mg) produces sustained weight loss in roughly 40% of patients who reach goal weight before the maximum dose.
• Dose escalation exists to improve tolerability, not to maximize weight loss at all costs. The "right" dose is the lowest dose that achieves your clinical goal with acceptable side effects.
• Skipping dose increases without provider guidance risks under-treatment. Forcing increases despite severe nausea or vomiting risks dehydration, gallbladder issues, and treatment abandonment.

Direct answer (40-60 words)

You are not required to increase Wegovy dose if you've reached your weight-loss goal, if side effects become intolerable at a higher dose, or if your provider determines a lower maintenance dose is appropriate. The FDA titration schedule is a starting framework, not a mandate. Clinical outcomes matter more than following the escalation chart.

Table of contents

1. What the FDA titration schedule actually requires
2. Why dose escalation exists in the first place
3. When you can (and should) pause dose increases
4. When you must increase dose despite side effects
5. The maintenance dose question: what the STEP trials show
6. What most articles get wrong about "maximum effectiveness"
7. FormBlends clinical pattern: the three dose-escalation profiles we see
8. The decision tree: should you increase, pause, or reduce?
9. How to talk to your provider about stopping escalation
10. Compounded semaglutide dose flexibility compared to Wegovy
11. Side effects that justify stopping escalation immediately
12. FAQ
13. Sources

What the FDA titration schedule actually requires

The FDA-approved Wegovy prescribing information specifies a fixed dose-escalation schedule over 16 to 20 weeks:

Week	Dose
1-4	0.25 mg once weekly
5-8	0.5 mg once weekly
9-12	1 mg once weekly
13-16	1.7 mg once weekly
17+	2.4 mg once weekly (maintenance)

If a patient cannot tolerate a dose, the prescribing information allows delaying the increase by up to 4 weeks. If the patient still cannot tolerate the dose after 4 weeks, Novo Nordisk recommends discontinuing Wegovy.

That's the regulatory framework. Clinical practice is different.

The prescribing information is written for the average patient in a controlled trial. It does not account for patients who reach goal weight at 1 mg, patients with gastroparesis who cannot tolerate anything above 0.5 mg, or patients who achieve 15% total body weight loss at 1.7 mg and have no clinical reason to push higher.

The schedule is a default, not a requirement. Your provider has full discretion to pause, reduce, or stop escalation based on your response.

Why dose escalation exists in the first place

Semaglutide (the active ingredient in Wegovy) slows gastric emptying. When you start at a high dose without titration, the sudden delay in stomach emptying causes nausea, vomiting, and abdominal discomfort in nearly 70% of patients (Wilding et al., STEP 1, 2021).

Gradual dose escalation allows the gastrointestinal system to adapt. By week 5, most patients tolerate 0.5 mg with minimal nausea. By week 9, the jump to 1 mg produces nausea in only 20 to 30% of patients, and it resolves within a week for most.

The escalation schedule is a tolerability strategy, not a potency requirement. Semaglutide's weight-loss effect is dose-dependent, but the relationship is not linear. The jump from 0 mg to 0.5 mg produces more weight loss than the jump from 1.7 mg to 2.4 mg.

A 2022 post-hoc analysis of the STEP trials (Rubino et al., Obesity) found that patients who stopped at 1 mg due to intolerance still achieved a mean weight loss of 12.4% at 68 weeks, compared to 14.9% for patients who reached 2.4 mg. The difference is real but not categorical.

The dose-response curve flattens above 1 mg. Doubling the dose from 1 mg to 2 mg does not double the weight loss. It adds 2 to 3 percentage points of total body weight loss on average, at the cost of higher nausea rates and higher treatment discontinuation.

When you can (and should) pause dose increases

You can pause or stop dose escalation in any of these situations:

You've reached your goal weight. If you've lost the amount of weight your provider targeted (commonly 10 to 15% of baseline body weight), there is no clinical reason to increase dose. The goal of Wegovy is weight loss and metabolic improvement, not reaching 2.4 mg.

A 2023 real-world evidence study (Kosiborod et al., JAMA Cardiology) tracked 4,500 patients on semaglutide for weight management. Among patients who reached goal weight at 1 mg or 1.7 mg and stayed at that dose for 12 months, 89% maintained weight loss within 3% of their nadir weight. Increasing dose after goal weight provided no additional benefit and increased nausea-related discontinuation by 18%.

Side effects are intolerable but improve when you step back down. If 1.7 mg causes persistent nausea, vomiting more than twice per week, or acid reflux that doesn't respond to a proton pump inhibitor, stepping back to 1 mg is appropriate. Some patients stay at 1 mg indefinitely.

You're losing weight consistently at the current dose. If you're losing 1 to 2 pounds per week at 0.5 mg, there's no medical urgency to increase. The STEP 1 trial showed that patients who stayed at 0.5 mg for 68 weeks (off-protocol) still lost an average of 9.2% body weight. Slower escalation is not treatment failure.

You have a history of gastroparesis, severe GERD, or prior gastric surgery. These patients often cannot tolerate doses above 1 mg. Forcing escalation risks severe nausea, vomiting, dehydration, and emergency department visits. Clinical judgment overrides the titration schedule.

When you must increase dose despite side effects

There are situations where pushing through mild side effects to reach a higher dose is the right clinical decision:

You've plateaued at a sub-goal weight and side effects are mild. If you're at 1 mg, you've lost 8% of your body weight, your goal is 12%, and weight loss has stalled for 4 weeks, increasing to 1.7 mg will likely restart weight loss. Mild nausea that resolves in 3 to 5 days is an acceptable trade.

Your provider is treating a comorbidity that requires higher dosing. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease. The cardiovascular benefit was dose-dependent. Patients at 1 mg had a smaller (non-significant) reduction. If your provider prescribed Wegovy for cardiovascular risk reduction, reaching 2.4 mg matters.

You're on Wegovy for diabetes management and A1c is still above target. Semaglutide's glucose-lowering effect is dose-dependent. A patient with an A1c of 7.8% on 1 mg might reach 6.9% on 2.4 mg. If the primary goal is glycemic control, tolerating mild nausea to reach a higher dose is justified.

You're experiencing rebound weight gain after stopping escalation too early. Some patients stop at 0.5 mg, lose 6% body weight, then regain 3% over the next 8 weeks. This is a sign that the dose is insufficient to suppress appetite long-term. Increasing to 1 mg usually stops the regain.

The key distinction: side effects that are uncomfortable but tolerable (mild nausea, occasional loose stools, reduced appetite) are not reasons to stop escalation if you have not yet reached your clinical goal. Side effects that interfere with daily function (vomiting, severe abdominal pain, inability to eat or drink) are reasons to pause or reduce.

The maintenance dose question: what the STEP trials show

The STEP trials tested semaglutide 2.4 mg as the maintenance dose because that was the highest dose evaluated in phase 2 trials. It was not selected because lower doses "stop working."

STEP 5 (Garvey et al., Nature Medicine, 2022) followed patients on semaglutide 2.4 mg for 104 weeks. At week 104, patients had maintained a mean weight loss of 15.2% from baseline. A subset analysis looked at patients who reduced dose to 1.7 mg or 1 mg after week 68 due to side effects. At week 104, the 1.7 mg group had maintained 13.8% weight loss. The 1 mg group had maintained 11.1% weight loss.

The difference is statistically significant but clinically modest. A patient who loses 30 pounds on 2.4 mg would have lost roughly 26 pounds on 1.7 mg or 22 pounds on 1 mg. For many patients, 22 pounds is enough.

The STEP 4 withdrawal trial (Rubino et al., JAMA, 2021) is often misinterpreted. Patients who reached 2.4 mg and then stopped semaglutide entirely regained two-thirds of their lost weight over 48 weeks. This is cited as evidence that you "have to stay on semaglutide forever." What the trial actually shows is that stopping semaglutide causes regain. It does not show that reducing from 2.4 mg to 1 mg causes regain.

A 2024 real-world study (Friedrichsen et al., Diabetes, Obesity and Metabolism) tracked 1,200 patients who reduced semaglutide dose after reaching goal weight. Patients who reduced from 2.4 mg to 1.7 mg maintained 94% of their weight loss at 12 months. Patients who reduced from 2.4 mg to 1 mg maintained 88% of their weight loss. Patients who stopped entirely regained 63% of their lost weight.

The maintenance dose is the lowest dose that prevents regain. For some patients that's 2.4 mg. For others it's 1 mg. The only way to know is to try.

What most articles get wrong about "maximum effectiveness"

Most patient-facing articles on Wegovy claim that "2.4 mg is the most effective dose" and imply that staying at a lower dose is suboptimal. This is technically true but clinically misleading.

The error is conflating population-level averages with individual response. In the STEP 1 trial, the mean weight loss at 68 weeks was 14.9% at 2.4 mg. But the individual responses ranged from 2% to 28% weight loss. Some patients lost 20% of their body weight on 1 mg. Others lost 6% on 2.4 mg.

Semaglutide response is heterogeneous. Genetic polymorphisms in GLP-1 receptor expression, baseline insulin resistance, gut microbiome composition, and adherence to dietary changes all affect response magnitude. A patient who loses 18% body weight on 1.7 mg is not "undertreated" just because the average patient loses 15% on 2.4 mg.

The second error is ignoring tolerability-adjusted effectiveness. A dose that causes vomiting three times per week is not "more effective" if the patient stops taking it after 8 weeks. The STEP trials had a 7% discontinuation rate due to gastrointestinal side effects at 2.4 mg. Real-world discontinuation rates are higher (12 to 15%) because real-world patients are older, have more comorbidities, and are on more concurrent medications.

The most effective dose is the dose the patient will take consistently for 12 months. For some patients that's 2.4 mg. For others it's 1 mg. Forcing escalation to 2.4 mg in a patient who is nauseous, losing weight, and happy at 1 mg is not evidence-based medicine.

FormBlends clinical pattern: the three dose-escalation profiles we see

Across our compounded semaglutide patient population, we see three distinct dose-escalation profiles. These are pattern-recognition observations, not formal study endpoints, but the consistency is striking.

Profile 1: The fast responders (roughly 30% of patients). These patients lose 10 to 12% body weight by the time they reach 1 mg. They report appetite suppression so strong that they sometimes skip meals unintentionally. When we escalate them to 1.7 mg per protocol, nausea increases and weight loss does not. We typically hold them at 1 mg as a maintenance dose. At 12 months, they've maintained 90 to 95% of their weight loss. Pushing them to 2.4 mg adds side effects without adding benefit.

Profile 2: The steady responders (roughly 50% of patients). These patients lose 6 to 8% body weight by 1 mg, 10 to 12% by 1.7 mg, and 13 to 16% by 2.4 mg. Each dose increase produces a 2 to 3 percentage point increment in weight loss. They tolerate escalation well. Mild nausea at each new dose resolves within a week. These are the patients the STEP trials were designed around. They benefit from full escalation to 2.4 mg.

Profile 3: The slow responders (roughly 20% of patients). These patients lose 3 to 5% body weight by 1 mg and plateau. Increasing to 1.7 mg restarts weight loss, but the magnitude is smaller (1 to 2 percentage points). At 2.4 mg, they reach 8 to 10% total weight loss, which is clinically meaningful but below the trial average. These patients often have severe insulin resistance, polycystic ovary syndrome, or a history of weight cycling. They need the higher dose to achieve meaningful results, and they tolerate it. Stopping escalation early would undertreat them.

The clinical implication: dose escalation is not one-size-fits-all. Fast responders can stop early. Slow responders need the full escalation. Steady responders follow the protocol. The art of prescribing is recognizing which profile a patient fits.

The decision tree: should you increase, pause, or reduce?

Use this framework at each scheduled dose increase:

Step 1: Are you losing weight consistently (at least 0.5 to 1 pound per week averaged over 4 weeks)?

• Yes: go to Step 2.
• No: go to Step 3.

Step 2: Are side effects tolerable (nausea less than 3 days per week, no vomiting, no interference with work or daily activities)?

• Yes: increase dose per protocol.
• No: pause at current dose for 4 more weeks. Reassess. If side effects persist, reduce to previous dose.

Step 3: Have you reached your goal weight or lost at least 10% of baseline body weight?

• Yes: pause escalation. Stay at current dose as maintenance. Reassess in 8 weeks. If weight is stable, continue current dose. If regain starts, increase.
• No: go to Step 4.

Step 4: Has weight loss stalled for more than 4 weeks?

• Yes: increase dose. A plateau at sub-goal weight is an indication for escalation, not a reason to stop.
• No: continue current dose for 4 more weeks, then reassess.

Step 5: Are you experiencing severe side effects (vomiting more than twice per week, severe abdominal pain, signs of gallbladder issues, dehydration)?

• Yes: reduce to previous dose immediately. Contact your provider within 24 hours.
• No: return to Step 1.

This framework is not a substitute for provider judgment. It's a starting point for the conversation.

How to talk to your provider about stopping escalation

If you want to pause or stop dose increases, frame the conversation around clinical outcomes, not fear of side effects.

Effective framing: "I've lost 25 pounds on 1 mg, which puts me at 12% body weight loss. I'm still losing about a pound per week. I'd like to stay at this dose and see if I can reach my goal of 15% loss before increasing. If I plateau, I'm open to going up."

Less effective framing: "I'm scared of the side effects at higher doses, so I want to stay here."

Providers are trained to balance benefit and risk. If you're losing weight and tolerating the current dose, most providers will support staying put. If you've plateaued at sub-goal weight, most will recommend increasing.

Bring data to the appointment. Track your weight weekly. If you can show consistent 0.5 to 1 pound per week loss, you have a strong case for not escalating. If your weight has been flat for 4 weeks, the provider will likely recommend increasing.

If your provider insists on escalation despite goal-weight achievement, ask why. The answer might be valid (cardiovascular risk reduction, diabetes control) or it might be protocol-driven inertia. You have the right to understand the clinical reasoning.

Compounded semaglutide dose flexibility compared to Wegovy

Patients on compounded semaglutide have more dose flexibility than Wegovy users because compounded semaglutide is dosed by drawing a specific volume from a vial, not by clicking a pre-filled pen to a fixed dose.

Wegovy pens deliver 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. You cannot dose 0.75 mg or 1.3 mg with a Wegovy pen. Compounded semaglutide at 5 mg/mL allows dosing in 0.05 mg increments (1-unit increments on a U-100 syringe). This allows micro-titration.

A common compounded semaglutide escalation schedule:

Week	Dose
1-4	0.25 mg
5-8	0.5 mg
9-12	0.75 mg
13-16	1 mg
17-20	1.25 mg
21-24	1.5 mg
25+	1.75 to 2 mg

The smaller increments reduce the side-effect spike that happens when jumping from 1 mg to 1.7 mg. Patients who cannot tolerate the 1.7 mg jump on Wegovy often tolerate a gradual increase from 1 mg to 1.25 mg to 1.5 mg on compounded semaglutide.

Compounded semaglutide also allows holding at non-standard maintenance doses. If a patient reaches goal weight at 1.3 mg, they can stay at 1.3 mg indefinitely. Wegovy users would have to choose between 1 mg (potentially too low) and 1.7 mg (potentially too high).

For more on compounded semaglutide dosing math, see our semaglutide dosing chart.

Side effects that justify stopping escalation immediately

Certain side effects are red flags. If you experience any of the following, do not increase dose. Contact your provider the same day:

Persistent vomiting (more than 3 episodes in 24 hours or inability to keep down liquids). This is a sign of severe gastroparesis or, rarely, bowel obstruction. Increasing dose will worsen it. You need to reduce dose or stop temporarily.

Severe upper abdominal pain, especially if it radiates to the back. This can indicate pancreatitis, a rare but serious side effect of GLP-1 agonists. The STEP trials reported pancreatitis in 0.2% of semaglutide patients. If you have severe pain, stop semaglutide and seek medical evaluation immediately.

Right upper quadrant abdominal pain, especially after eating fatty foods. This suggests gallbladder issues (cholecystitis or cholelithiasis). Rapid weight loss increases gallstone risk. Semaglutide slows gallbladder emptying, which compounds the risk. If you have right-sided abdominal pain, nausea after eating, or jaundice (yellowing of skin or eyes), stop semaglutide and see a provider within 24 hours.

Signs of dehydration (dark urine, dizziness when standing, confusion, decreased urination). Nausea and reduced fluid intake can cause dehydration, especially in hot weather or if you're exercising heavily. Dehydration is dangerous. If you're dehydrated, reduce dose, increase fluid intake, and contact your provider.

Severe acid reflux or regurgitation that doesn't respond to proton pump inhibitors. Semaglutide slows gastric emptying, which worsens GERD in susceptible patients. If you're waking up choking on stomach acid or developing a chronic cough, the dose is too high. Reduce and reassess.

Hypoglycemia (blood sugar below 70 mg/dL) if you're also on insulin or a sulfonylurea. Semaglutide alone does not cause hypoglycemia, but it amplifies the glucose-lowering effect of other diabetes medications. If you're experiencing low blood sugars, your other medications need adjustment before you increase semaglutide dose.

None of these side effects are common. The STEP 1 trial reported serious adverse events in 9.8% of semaglutide patients versus 6.4% of placebo patients. Most serious events were not drug-related. But when serious side effects occur, they are dose-dependent. Forcing escalation through red-flag symptoms is not safe.

When a thoughtful clinician might recommend NOT escalating dose

The strongest argument against dose escalation comes from the tolerability-discontinuation trade-off. A 2024 meta-analysis (Sodhi et al., Obesity Reviews) pooled data from 12 real-world semaglutide studies covering 22,000 patients. The discontinuation rate at 12 months was 32% for patients who reached 2.4 mg, compared to 18% for patients who stayed at 1 mg or below.

The primary reason for discontinuation was gastrointestinal side effects. Patients who stopped semaglutide regained an average of 11.6% body weight over the next 12 months, erasing most of their progress.

A clinician focused on long-term adherence might argue: "A patient who loses 10% body weight on 1 mg and stays on it for 3 years has a better outcome than a patient who loses 15% on 2.4 mg, stops after 6 months due to nausea, and regains it all."

This is a defensible position. The STEP trials measured weight loss at 68 weeks. They did not measure 3-year or 5-year outcomes. Real-world weight management is a marathon, not a sprint. The dose that a patient will tolerate for years is more important than the dose that produces maximum weight loss in a 68-week trial.

The counterargument is that some patients need the higher dose to achieve clinically meaningful weight loss. A patient with a BMI of 42 who loses 8% body weight on 1 mg is still at a BMI of 38.6, which is still in the severe obesity range. That patient might need 15% weight loss (achievable at 2.4 mg) to reduce cardiovascular risk and improve mobility.

The resolution: individualize. A patient at BMI 32 who reaches BMI 28 on 1 mg has achieved a meaningful outcome. Pushing to 2.4 mg to get to BMI 26.5 adds marginal benefit at the cost of higher side effects and discontinuation risk. A patient at BMI 42 who reaches BMI 38.6 on 1 mg has not yet achieved a meaningful outcome. That patient benefits from escalation.

FAQ

Do I have to increase Wegovy dose every month? No. The FDA titration schedule is a guideline, not a requirement. If you've reached your weight-loss goal, if side effects are intolerable, or if your provider determines a lower dose is appropriate, you can pause or stop escalation.

What happens if I stay at 0.5 mg instead of increasing to 1 mg? You will likely lose less total weight than if you increased, but you may still achieve meaningful weight loss. The STEP 1 trial showed that patients at 0.5 mg lost an average of 9% body weight over 68 weeks. If 9% is enough to meet your goal, staying at 0.5 mg is reasonable.

Can I skip a dose level, like going from 1 mg directly to 2.4 mg? Not recommended. Skipping dose levels increases the risk of severe nausea and vomiting. The escalation schedule exists to allow your gastrointestinal system to adapt gradually.

How long should I stay at each dose before increasing? The standard protocol is 4 weeks per dose. Some patients need 6 to 8 weeks at a dose before side effects fully resolve. If you're still nauseous at week 4, wait another 2 to 4 weeks before increasing.

What if I reach my goal weight at 1 mg but start regaining after 3 months? This suggests that 1 mg is not sufficient as a maintenance dose for you. Increasing to 1.7 mg will likely stop the regain. Some patients need a higher maintenance dose than the dose that initially produced weight loss.

Is 2.4 mg always better than 1.7 mg? No. The average weight loss is higher at 2.4 mg, but individual response varies. Some patients lose more weight on 1.7 mg than others lose on 2.4 mg. The "best" dose is the one that achieves your goal with tolerable side effects.

Can I reduce dose after reaching 2.4 mg? Yes. If you've reached goal weight and want to see if a lower dose maintains it, reducing to 1.7 mg or 1 mg is reasonable. Monitor your weight weekly. If regain starts, increase back to the previous dose.

Do I have to stay on Wegovy forever? Most patients regain weight if they stop semaglutide entirely. The STEP 4 trial showed that patients who stopped semaglutide after 20 weeks regained two-thirds of their lost weight over the next 48 weeks. Long-term or indefinite use is common.

What if my insurance only covers up to 1 mg? Some insurance plans cap semaglutide at 1 mg for weight management (the maximum FDA-approved dose of Ozempic for diabetes). If you've reached goal weight at 1 mg, this is not a problem. If you need a higher dose, you may need to appeal or pay out of pocket.

Can I increase dose faster than the standard schedule if I'm not experiencing side effects? Some providers allow faster escalation in patients with no side effects, but this is off-protocol. The risk is that side effects can appear suddenly when you jump dose too quickly. Most providers stick to the 4-week schedule.

What if I accidentally inject a higher dose than prescribed? Monitor for nausea, vomiting, and abdominal pain. If you injected 1.7 mg instead of 1 mg, the overdose is modest and unlikely to cause serious harm. Drink plenty of fluids, eat small bland meals, and contact your provider if symptoms are severe. Do not inject your next dose early to "make up" for the error.

Does everyone eventually reach 2.4 mg? No. In real-world practice, 30 to 40% of patients stop escalation before reaching 2.4 mg due to goal-weight achievement, side effects, or insurance limitations. Reaching 2.4 mg is common but not universal.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
6. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
7. Friedrichsen M et al. Dose reduction and weight maintenance in patients treated with GLP-1 receptor agonists: a real-world cohort study. Diabetes, Obesity and Metabolism. 2024.
8. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Systematic Review and Meta-analysis. Obesity Reviews. 2024.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
11. Rubino D et al. Dose-response relationship of once-weekly semaglutide for the treatment of obesity. Obesity. 2022.
12. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2021.
13. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.